Status:
COMPLETED
Lucentis Versus Mitomycin C During Glaucoma Surgery
Lead Sponsor:
Wills Eye
Collaborating Sponsors:
Genentech, Inc.
Novartis Pharmaceuticals
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while ...
Detailed Description
This is an open-label, single center trial with two arms for patients who underwent guarded filtration surgery to control glaucoma. The control will consist of patients randomly assigned to receive in...
Eligibility Criteria
Inclusion
- 18 yrs or older
- patients requiring first time glaucoma filtering surgery
- phakic or pseudophakic
- must provide written informed consent and comply with study assignments
Exclusion
- Pregnant, lactation or premenopausal women not using adequate contraception.
- Previous glaucoma surgery, tube shunt surgery, pars plana vitrectomy, scleral buckle, penetrating keratoplasty.
- Abnormality preventing reliable applanation tonometry in each eye.
- Current infection or inflammation in either eye.
- Enrolled in another investigational study.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00626782
Start Date
January 1 2008
End Date
April 1 2011
Last Update
March 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wills Eye Hospital, Glaucoma Service
Philadelphia, Pennsylvania, United States, 19107